Macrobid is approved for uncomplicated lower urinary tract infections only. Pyelonephritis is a more severe, upper-tract infection that typically requires broader-spectrum antibiotics and is not an indication for nitrofurantoin.
A cough may signal early pulmonary toxicity, which can be serious. Stop the medication and contact a healthcare professional promptly for evaluation.
There is no known interaction between nitrofurantoin and hormonal contraceptives. The antibiotic should not reduce contraceptive effectiveness.
Both strengths are round, white tablets, but the imprint codes differ: the 50 mg tablets typically bear “M 50” while the 100 mg tablets bear “M 100.” Imprint details may vary by manufacturer.
Nitrofurantoin metabolites are excreted in the urine, but standard drug-screening panels do not test for this antibiotic. Routine urine tests for infection will not be affected.
Nitrofurantoin is ineffective against infections associated with indwelling catheters because adequate drug concentrations are not achieved in the upper urinary tract. Alternative antibiotics are recommended.
Elderly patients often have reduced renal function. Before prescribing, clinicians should evaluate kidney performance and may opt for a lower dose or a different agent.
Inappropriate or incomplete courses of any antibiotic can promote resistance. Completing the full prescribed course of Macrobid helps minimize this risk.
Dietary calcium does not interfere with nitrofurantoin absorption. However, calcium-containing antacids may reduce absorption and should be timed apart from the dose.
Macrobid can be prescribed on the NHS, but coverage depends on the specific clinical indication and local formulary policies. Prescription charges may apply unless exempt.
Macrobid is a brand-name antibiotic that contains nitrofurantoin macrocrystals as its active component. It is supplied as oral pill tablets in strengths of 50 mg and 100 mg. Nitrofurantoin belongs to the antibiotics class and is primarily prescribed for uncomplicated urinary tract infections (UTIs) caused by susceptible bacteria. In the United Kingdom, Macrobid is a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Nitrofurantoin exerts its antibacterial effect after it is reduced by bacterial flavoprotein enzymes inside susceptible microorganisms. This reduction creates reactive intermediates that:
These actions are bactericidal, meaning they kill the bacteria rather than merely inhibiting their growth. Because nitrofurantoin is excreted unchanged in the urine, it achieves high concentrations in the bladder and urinary tract, which is why it is effective for UTIs. Onset of action typically occurs within a few hours after dosing, with peak urinary concentrations reached after about 2-4 hours. The drug is eliminated primarily by the kidneys; therefore, adequate renal function is essential for its therapeutic effect.
Macrobid is approved in the UK for the treatment of uncomplicated lower urinary tract infections caused by susceptible strains of Escherichia coli, Enterococcus faecalis, Staphylococcus saprophyticus, and other common uropathogens. It is intended for adult patients whose infection is limited to the bladder (cystitis) and who have normal or mildly reduced renal function (creatinine clearance ≥ 60 mL/min). Use in complicated infections, pyelonephritis, or prostatitis is not indicated.
This article provides educational information about Macrobid and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
